'''CRL-40,940''' (also known as '''flmodafinil''', '''bisfluoromodafinil''' and '''lauflumide''') is a selective dopaminergic reuptake inhibitor, and is the bisfluoro [[Structural analog|analog]] of the [[eugeroic]] [[modafinil]] and has been sold online as a [[designer drug]].<ref>{{cite web | url=https://www.google.com/patents/CA1199916A1 | title=Patent CA 1199916 A1 - Benzhydrylsulfinylacetamide derivatives | author=Louis Lafon | date=28 January 1986 | accessdate=25 July 2015}}</ref><ref>{{cite journal | title=SARs at the Monoamine Transporters for a Novel Series of Modafinil Analogues |author1=Jianjing Cao |author2=Thomas E. Prisinzano |author3=Oluyomi M. Okunola |author4=Theresa Kopajtic |author5=Matthew Shook |author6=Jonathan L. Katz |author7=Amy Hauck Newman | journal=ACS Medicinal Chemistry Letters |date=January 2011  | volume=2 | issue=1 | pages=48â€“52 | doi=10.1021/ml1002025 | pmid=21344069 | pmc=3041981}}</ref><ref>{{cite web | url=https://www.google.com/patents/US20130295196 | title=Patent US 20130295196 A1 - Lauflumide and the enantiomers thereof, method for preparing same and therapeutic uses thereof | date=7 November 2013 | accessdate=25 July 2015 | author=Eric Konofal}}</ref><ref>{{cite web | url=https://www.google.com/patents/US4489095 | title=Patent US 4489095 A - Halogenobenzhydrylsulfinylacetohydroxamic acids | date=18 December 1984 | accessdate=25 July 2015 | author=Louis Lafon}}</ref> Its inventors claim that it is more effective than modafinil and adrafinil in their indications with fewer side effects, and was patented in 2013.<ref>http://www.google.com/patents/US20130295196</ref> Phase I clinical trials have been underway since December 2015.<ref>http://nlspharma.com/science/pipeline/</ref><ref>http://adisinsight.springer.com/drugs/800043932</ref>
